DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Thalidomide
Thalidomide
Thalidomide Celgene Pregnancy Prevention Programme Information
Study Protocol and Statistical Analysis Plan
Cancer Drug Pharmacology Table
Adverse Effects in Women: Implications for Drug Development and Regulatory Policies
New Drugs Are Not Enough‑Drug Repositioning in Oncology: an Update
Thalidomide and Pregnancy
Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: from Discovery to Implementation
Thalidomide Pregnancy Prevention Programme Information For
Volume , Number
Thalidomide in Leprosy Do Not Require Any Specific Treatment Except with Some Thalidomide: a Few Years Later, However, the Analgesics/Antipyretics
2021 Formulary List of Covered Prescription Drugs
Recent Advances in the Management of Hormone Refractory Prostate Cancer
CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS
A Pharmacogenetic Study of Docetaxel and Thalidomide in Patients with Castration-Resistant Prostate Cancer Using the DMET Genotyping Platform
Cancer Drug Costs for a Month of Treatment at Initial Food
POMALYST Safely Capsules: 1 Mg, 2 Mg, 3 Mg, and 4 Mg (3) and Effectively
Thalidomide Pharmion, Which Was Designated As an Orphan Medicinal Product EU/3/01/067 on 20 November 2001
Thalidomide (Thalomid®) (“Tha-LI-Doe-Mide”)
Top View
Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
BICALUTAMIDE -- Withdrawn Due to Accelerated Deaths
Appendix B - Product Name Sorted by Applicant
Thalidomide Metabolism by the CYP2C Subfamily1
Thalidomide-Celgene-Epar-Product
Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice
Invited Lecture Presented at the Canadian Society of Pharmacology and Therapeutics Annual Meeting
The Hitchhiker's Guide to Clinical Pharmacology
Pharmaceutical Compositions and Dosage Forms of Thalidomide
FEP 5 Tier Rx Drug Formulary (607) Standard Option
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2014
Thalidomide: the Tragedy of Birth Defects and the Effective Treatment of Disease
Thalidomide Does Not Interact with P-Glycoprotein
THALOMID U.S. Prescribing Information
Early Refill Drug Utilization Review Drugs
A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-Independent Prostate Cancer1
1. NAME of the MEDICINAL PRODUCT <Invented Name> 50 Mg
Novel Chiral LC Methods for the Enantiomeric Separation of Bicalutamide and Thalidomide on Amylose Based Immobilized CSP